Table 1.

Patient Characteristics.

	All Patients		Early POD, <24 mo		Late POD, ≥24 mo		P
	n	%	n	%	n	%
	149		51	34	98	66
Sex
Female	32	21	9	18	23	23	0.41
Male	117	79	42	82	75	77
Trial
MCL2	78	52	26	51	52	53	0.81
MCL3	71	48	25	49	46	47
ASCT in front line
Yes	126	85	35	69	91	93	<0.001
No	23	15	16	31	7	7
At first POD:
Median age	61 (IQR 57-65)		61 (IQR 55-64)		61 (IQR 57-67)		0.14
CNS involvement (n = 118)
No	111	94	37	88	74	97	0.10
Yes	7	6	5	12	2	3
MIPI (n = 82)
LR	38	46	9	41	29	48	0.17
IR	19	23	3	14	16	27
HR	25	30	10	45	15	25
Ki67 (n = 43)
<30%	17	40	0	0	17	50	0.007
≥30%	26	60	9	100	17	50
At diagnosis:
Median age	57 (IQR 52-61)		59 (IQR 53-63)		56 (IQR 51-61)		0.036
MIPI (n = 147)
LR	57	39	9	18	48	49	<0.001
IR	41	28	13	26	28	29
HR	49	33	28	56	21	22
Ki67 (n = 128)
<30%	63	49	12	26	50	61	<0.001
≥30%	65	51	33	72	32	39
Blastoid (n = 149)
No	115	77	29	57	86	88	<0.001
Yes	34	23	22	43	12	12
TP53 mutated (n = 94)
No	69	73	12	40	57	89	<0.001
Yes	25	27	18	60	7	11

ASCT = autologous stem cell transplantation, CNS = central nervous system, HR = high-risk, IR = intermediate-risk, Ki67 = cell proliferation marker, LR = low-risk, MIPI = mantle cell lymphoma international prognostic index, POD = progression of disease.